Duchenne Research Fund News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Santhera Receives Approval for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy in the United Kingdom

Santhera Receives Approval for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy in the United Kingdom
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSwitzerland generalUnited kingdomEva kaliasShabir hashamLife science allianceEuropean unionRegulatory agencyHead investor relations communicationsSanthera pharmaceuticals holdingAmerica to catalyst pharmaceuticalsDuchenne research fundSanthera pharmaceuticalsEuropean medicines agencyEnergyx ray absorptiometryDrug administration

Santhera Receives Approval for AGAMREE® (Vamorolone) as a

Approval by the Medicines and Healthcare products Regulatory Agency (MHRA) of AGAMREE® in the United Kingdom follows marketing authorization for this.

United statesUnited kingdomSwitzerland generalShabir hashamEva kaliasEuropean medicines agencyAmerica to catalyst pharmaceuticalsEuropean unionLife science allianceHead investor relations communicationsRegulatory agencySanthera pharmaceuticals holdingSanthera pharmaceuticalsDuchenne research fundEnergyx ray absorptiometryEuropean commission

Santhera Pharmaceuticals Holding AG: Vamorolone NDA mid-cycle review meeting by FDA completed

Pratteln, Switzerland, and Rockville, MD, USA, April 25, 2023 - Santhera Pharmaceuticals (SIX: SANN) and ReveraGen BioPharma, Inc announce the successful completion of the mid-cycle review meeting

United statesSwitzerland generalUnited kingdomEric hoffmanEva kaliasShabir hashamReveragen biopharmaEuropean medicines agencySanthera pharmaceuticals holdingDrug administrationRegulatory agencyNational institutes of healthUs department of defenseReveragen biopharma incDuchenne research fundHead investor relations communications

Santhera Pharmaceuticals Holding AG: Santhera Submits Marketing Authorization Application to the UK MHRA for Vamorolone in Duchenne Muscular Dystrophy

Pratteln, Switzerland, March 2, 2023 - Santhera Pharmaceuticals (SIX: SANN) announces that it has submitted a marketing authorization application (MAA) to the UK Medicines and Healthcare products Regulatory

Switzerland generalUnited statesUnited kingdomDennis riedlShabir hashamEric hoffmanEva kaliasReveragen biopharmaLife science allianceSanthera pharmaceuticalsMuscular dystrophy association united statesNational institutes of healthDuchenne research fundFoundation to eradicate duchenneDrug administrationRegulatory agency

Using motion capture technology and AI to monitor the progression of movement disorders

A multi-disciplinary team of researchers has developed a way to monitor the progression of movement disorders using motion capture technology and AI.

United kingdomCity ofValeria ricottiAldo faisalRichard festensteinBalasundaram kadirveluThomas voitPaola giuntiEmily hendersonUniversity college londonUnited kingdom medical research councilImperial college biomedical research centreAtaxia centreQueen square institute of neurologyImperial college london departments of computingInstitute for child health